EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinie

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations

Jeremy DiGennaro, David A Sallman

Acta Haematologica · 2024

DOI: 10.1159/000535628 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2024. Verfasst von Jeremy DiGennaro und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by uncontrolled proliferation and impaired differentiation of myeloid cells in the bone marrow. The tumor suppressor gene TP53 plays a crucial role in maintaining genomic integrity and preventing the development of cancer. TP53 mutations are frequently observed in AML (∼10% of patients) and are associated with aggressive disease behavior, resistance to therapy, and poor prognosis. Summary: Recent changes in classification of TP53-mutated myelodysplastic syndrome (MDS) have occurred related to the allelic status of TP53 and more importantly to harmonize MDS/AML patients as a homogeneous hematological malignancy. Current treatment regimens involve hypomethylating agents +/− venetoclax or intensive chemotherapy although unfortunately independent of treatment regimen the overall survival (OS) of this patient cohort is around 6 months with poor long-term outcomes after allogeneic stem-cell transplantation. Recent developments geared toward the treatment of TP53-mutated MDS/AML have focused on immunotherapies. Key Messages: Notably, there is optimism surrounding these new therapies that could provide breakthroughs with improving outcomes either as monotherapy or combined with established nonimmune therapies. This paper aims to provide an overview of TP53-mutated MDS/AML, including the underlying mechanisms, clinical implications, and emerging therapeutic strategies targeting this hematologic malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHematologic NeoplasmsHumansTumor Suppressor Protein p53Mutation

Stichwörter der Autor:innen

Acute myeloid leukemiaBiallelic TP53 mutationMyelodysplastic syndromeTP53 mutations

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Zitieren

APA

DiGennaro, J., & Sallman, D. A. (2024). TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations. Acta Haematologica. https://doi.org/10.1159/000535628

Vancouver

DiGennaro J, Sallman DA. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations. Acta Haematologica. 2024. doi:10.1159/000535628

BibTeX
@article{DiGennaro2024,
  author = {DiGennaro, Jeremy and Sallman, David A},
  title = {TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000535628}
}
Kostenlos starten →